Prelude Therapeutics Incorporated (PRLD) is a publicly traded Healthcare sector company. As of August 11, 2026, PRLD trades at $4.95 with a market cap of $390.26M and a P/E ratio of -4.87. PRLD moved +2.46% today. Year to date, PRLD is +66.55%; over the trailing twelve months it is +463.26%. Its 52-week range spans $0.61 to $5.69. Analyst consensus is buy with an average price target of $8.00. Rallies surfaces PRLD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for PRLD, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $4.95 |
| Market Cap | $390.26M |
| P/E Ratio | -4.87 |
| EPS | $-1.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.69 |
| 52-Week Low | $0.61 |
| Volume | 278 |
| Avg Volume | 0 |
| Revenue (TTM) | $16.72M |
| Net Income | $-77.80M |
| Gross Margin | 0.00% |
1 analysts cover PRLD: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $8.00.